Analysis of DNA copy number changes using comparative genomic hybridization in melanocytic neoplasms has revealed distinct patterns of chromosomal aberrations between benign melanocytic nevi and melanoma. Whereas the vast majority of melanoma expresses chromosomal aberrations, blue nevi, congenital nevi, and most Spitz nevi typically show no aberrations. A subset of Spitz nevi shows an isolated gain of chromosome 11p, an aberration pattern not observed in melanoma. These Spitz nevi frequently harbor mutations in the HRAS gene located on this chromosomal arm. Comparisons among melanoma types showed that melanomas of the palms, soles, and subungual sites can be distinguished by the presence of multiple gene amplifications that arise very early in their progression. About 50% of these amplifications are found at the cyclin D1 locus. By contrast, amplifications are significantly less frequent in other cutaneous melanoma types and if present arise late in progression. The frequent amplifications in melanomas on acral sites allowed the detection of single basal melanocytes with gene amplifications in the histologically normal appearing skin immediately adjacent to a melanoma. These ''field cells'' represent subtle melanoma in situ and are likely to represent minimal residual disease that can lead to local recurrences if not excised with safety margins. The high frequency of chromosomal aberrations in melanomas and their relative absence in nevi could indicate that melanocytes of melanomas went through telomeric crisis, whereas melanocytes in nevi did not. Such a scenario would suggest that replicative senescence is a tumor-suppressive mechanism in melanocytic neoplasia. It might also explain part of the phenomenon of regression commonly seen in melanoma.
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Patterns of chromosomal aberrations in melanocytic neoplasms
We have used comparative genomic hybridization (CGH) to perform genome-wide searches for patterns of aberrations that may be of help in the classification of melanocytic neoplasms. Using chromosome and arraybased CGH we have analysed several hundreds of benign and malignant melanocytic skin tumors. CGH can detect and map changes in DNA copy number in DNA samples including DNA extracted from archival specimens. Whereas the vast majority of melanomas showed chromosomal aberrations, the benign nevi mostly did not show aberrations. Whereas congenital nevi (Bastian et al., in press) and blue nevi (manuscript in preparation) did not show aberrations at all, a subset of Spitz nevi (about 20%) showed an isolated gain of chromosome 11p (Bastian et al., 1999) . The remainder of the Spitz nevi also did not show aberrations. Recent studies showed that this gain was because of the presence of multiple copies of an isochromosome 11p in the cells of these nevi (manuscript in preparation). Remarkably, this aberration does not appear to be present in melanomas. Spitz nevi can show significant histologic overlap with melanoma, leading to frequent misdiagnosis. (Barnhill et al., 1999) . The clearcut difference between the aberration patterns between nevi -no aberrations or presence of an isochromosome 11p -and melanoma -multiple chromosomal aberrations in over 95% of the casessuggests that chromosomal analyses may be of assistance in the classification of lesions that are ambiguous by histopathology. This aspect is of significant clinical relevance, because of the limitations of current techniques to classify reliably tumors that have overlapping histologic features (Farmer et al., 1996; Veenhuizen et al., 1997) .
A third pattern of chromosomal aberrations became apparent, when we analysed neoplasms that arose in congenital nevi during the neonatal period. Congenital nevi have an increased risk to progress to melanoma. However, during the first year of life, several types of melanocytic tumors can develop within congenital nevi, many of which are thought to be distinct from melanoma (DeDavid et al., 1997) . These tumors range widely in size, can grow very fast and ulcerate, and can be extremely difficult to classify histologically (Clark et al., 1990) . We analysed 10 cases of the rare atypical nodular proliferations that arise in congenital nevi during the first few months of life (Bastian et al., in press ). Although histologically these lesions simulate nodular melanoma, they tend to regress within a few months. Most of the cases did show chromosomal aberrations by CGH. However, different from melanoma, the aberrations involved only entire chromosomes. In melanomas gains or losses of entire chromosomes do occur frequently, but in 95% of the cases are paralleled by gains or losses of chromosomal fragments. Aberrations involving chromosomal fragments suggest abnormalities in handling double-stranded DNA breaks. However, an aberration pattern with numerical chromosomal aberrations only is suggestive of a malfunction in chromosomal segregation, possibly within the mitotic spindle checkpoint (Amon, 1999) . A control group of bona fide melanomas that arose in congenital nevi showed a pattern indistinguishable from melanoma. Mutation analyses on genes operating at the spindle checkpoint are underway.
Yet another pattern of chromosomal aberrations arose when different types of melanomas were analysed (Bastian et al., 2000a) . When compared to the most frequent melanoma type -superficial spreading melanoma -melanomas on acral skin invariably showed gene amplifications. Amplifications were defined as focused chromosomal regions with marked copy number increase (42.5-fold of ploidy). Whereas all acral melanomas appeared to have at least one amplification, most had several, less than 15% of nonacral melanomas had amplifications. Additional studies showed that the amplifications in acral melanomas arise very early in the progression, at or even before the in situ stage of the disease (see the section on field cells below). In contrast, the few nonacral melanomas that do display amplifications appear to have acquired them later during progression (unpublished data). The amplified regions in acral melanomas frequently contain known oncogenes such as HRAS (Bastian et al., 2000a) , cyclin D1 (Sauter et al., in press ), CDK4, HTERT, but also involve regions without obvious candidate genes.
When we compared the gene dosage of, for example, cyclin D1 we found that all cases with increased copy number overexpressed cyclin D1 protein (Sauter et al., in press) . However, about 25% of melanomas also overexpress cyclin D1 but do have normal copy number of the cyclin D1 gene. Antisense-mediated inhibition of cyclin D1 expression led to massive apoptosis in melanoma cell lines with cyclin D1 amplification, but not in normal melanocytes (Sauter et al., in press ). These findings support the notion that the amplifications target oncogenes and that gene amplifications are an essential mechanism of oncogene activation in acral melanomas. It appears possible that a distinct defect, for example, in the repair of double-stranded DNA breaks is responsible for the permissiveness for gene amplification in this melanoma type.
Spitz nevus as an example for incomplete transformation in melanocytic nevi
The isolated copy number increases of chromosome 11p in Spitz nevi raised the question as to which gene on 11p drives the selection forces that led to the accumulation of extra copies of that chromosomal arm. HRAS maps to the distal end of chromosome 11p, and cancers with mutations in ras gene frequently amplify the mutated allele. We sequenced the two hot spots for mutations in HRAS, codons 12, 13, and 61, and found that about 70% of the Spitz nevi with 11p copy number increases showed oncogenic mutations (Bastian et al., 2000b) . In addition, we found one out of 21 Spitz nevi with a normal copy number of 11p that had a mutation of HRAS. These findings suggest that HRAS is at least one target of the selection forces that lead to increasing copy numbers.
HRAS belongs to the family of ras genes, which contains the two additional members KRAS and NRAS (Barbacid, 1987) . NRAS mutations are found in about 25% of primary cutaneous melanomas (see Herlyn and Satyamoorthy, 1996 for a review). Interestingly, HRAS itself is rarely mutated in melanoma (van Elsas et al., 1996; Jiveskog et al., 1998) . In our series of cases there was no evidence that cases with HRAS mutations were at risk to progress to melanoma. The observation that the 11p copy number increase indicating an isochromosome 11p was not seen in over 300 melanomas, and melanoma cell lines studied so far further argues against the possibility that these Spitz nevi are precursors to melanoma.
It is well established that cancer is not caused by a mutation in a single gene, but requires genetic alterations affecting several pathways (Hanahan and Weinberg, 2000) . Ras genes are on their own insufficient to induce tumorigenesis but need cooperating oncogenes or inactivation of p53 or p16 in order to transform normal cells (Barbacid, 1987; Weinberg, 1989) . This is illustrated in neoplasms of the colon, where hyperplastic polyps, which only rarely progress to cancer, frequently have mutations of KRAS. In contrast, dysplastic polyps that carry a high risk of progression first acquire mutations of APC, which are then followed by ras mutations (Jen et al., 1994) . These findings indicate that not only the type of genes whose functions are altered is important, but also the order in which these alterations occur. The HRAS activation in Spitz nevi may be analogous to the KRAS activation in hyperplastic polyps. It could result in incompletely transformed melanocytes that share several features with melanoma cells but have a limited proliferative capacity.
Replicative senescence: the pivot point of melanocytic transformation?
In the last decade significant progress has been made in our understanding of the finite replicative lifespan of most human differentiated cells. Telomeres, the repetitive DNA sequences bound by a complex of proteins at the end of chromosomes, have been identified as the structures that prevent infinite division of somatic cells (Blackburn, 2001) . Telomeres shorten slightly with each cell division until they reach a critical length at which time a signal requiring p53 and RB is triggered, leading to permanent cell cycle arrest. This replicative senescence limits the number of cell divisions and is regarded as a major tumor-suppressive mechanism (Mathon and Lloyd, 2001) . Cells in which the damage signal is disabled (e.g. by mutations in the p53 or RB pathways) continue to proliferate beyond their normal lifespan. However, these cells cannot divide indefinitely -they are not yet immortal. After several additional rounds of cell division and progressive telomere attrition the chromosome ends become open DNA breaks, leading to end-toend fusion of sister chromatids, with subsequent dicentric chromosomes, and chromosome fragmentation during mitosis. The resulting genomic chaos results in a temporary marked increase in cell death, a phenomenon that is termed crisis in cell culture. At crisis, the cells carry on dividing but show high rates of apoptosis, which is triggered by gross chromosomal abnormalities.
Restabilization of chromosomes appears to be a requirement for cells to weather crisis (Sherr and DePinho, 2000) . Most human tumors including melanomas (Ramirez et al., 1999) stabilize their telomeres by expressing telomerase; the remainder stabilizes their telomeres by a different mechanism termed alternative lengthening of telomeres (ALT).
Our observation that melanomas tend to have marked chromosomal aberrations, whereas nevi do not, could indicate that melanomas have gone through crisis, whereas nevi have not. This would be supported by the observation that melanomas have activated telomerase, whereas nevi do not (Ramirez et al., 1999) . If this view were correct, the telomere checkpoint would be the major determinant whether an oncogenic mutation in a melanocyte would lead to a nevus or a melanoma. Mutations in an oncogene would lead to a clonal expansion of partially transformed melanocytes. However, this proliferation would eventually seize, if the senescence checkpoint were intact. In such a scenario one would predict an inverse correlation of nevus size and age at which the nevus is acquired. This fits well with what is observed clinically. Nevi that arise in utero can become extremely large, covering up to 50% or more of the body surface. Nevi acquired later in life never exceed the size of a few centimeters.
If the senescence checkpoint were not intact, any oncogenic mutation could drive proliferation into telomeric crisis and resulting chromosomal instability. After a transient period of genomic restructuring and selection, new clones would emerge that have become immortal and acquired an altered genome. This would represent a direct pathway to melanoma.
The senescence model would also allow an indirect pathway to melanoma in which melanoma arises from nevi. In this scenario the vast majority of the melanocytes making up the nevus have undergone senescence, whereas some of the melanocytes would escape the senescence mechanism and enter crisis. We have shown in several cases of melanomas that arose in melanocytic nevi that the chromosomal aberrations were present only in the melanoma part but not in the nevus part of the lesions, suggesting that they were acquired after or during the transformation to melanoma (Bastian et al., in press ).
Telomeric crisis and regression of melanoma
Telomere-induced crisis might also explain another phenomenon in melanoma progression. Primary cutaneous melanomas can occasionally regress. Regression is usually partial, affecting some areas of a primary lesion and sparing others, but occasionally melanoma tumors seem to vanish completely. Regression seems to occur more frequently in thin melanomas. In thicker melanomas it almost always affects the thin, radially growing areas. As melanoma progresses from thin, radially growing lesions, to thick vertical growing lesions, this suggests that regression is associated with relatively early progression.
Since infiltrates of antigen-specific lymphocytes can be demonstrated in regions of regression it is currently regarded as an immune-mediated phenomenon. However, immunological mechanisms cannot easily explain, why the regression is tied to a distinct progression phase, and only on exceptionally rare occasions affects the vertical growth phase of melanomas. In addition, if the immune system would represent an effective mechanism of melanoma suppression one would expect a significant increase in melanoma incidence in patients in which cellmediated immunity is impaired. However, while patients undergoing long-term immunosuppression have a dramatic increase in the incidence of cutaneous squamous cell carcinoma (about 70-fold), the melanoma incidence has been shown to be not or only moderately (three-to five-fold) increased (Glover et al., 1997; Lindelof et al., 2000) .
Cell death during telomeric crisis would be an alternate, hypothetical mechanism to explain regression in melanoma. We have previously shown that melanomas in the radial growth phase already show the marked chromosomal aberrations including amplification (Bastian et al., 1998 (Bastian et al., , 2000a . If crisis indeed contributes to these aberrations as suspected above, then crisis would have to precede the progression step associated with vertical growth phase.
In cell culture the cell death is massive, because one observes a more or less synchronous population reaching the point of critical telomere length almost simultaneously. If crisis occurred in real melanoma one would expect it to manifest itself in a more protracted way. The early phases of melanoma progression usually develop slowly, often over many years. During this period the clonal cell population is expected to loose synchronicity of their telomere length. Cells would therefore reach the stage of critical telomere length at separate time points rather than all together. Crisis would therefore be stretched out over a longer time period, characterized by a phase in which the apoptotic rate is higher than the proliferation rate, leading to a (temporal) decrease of cell number. The cancer is ''spinning its wheels'' and slipping backwards with regard to net cell proliferation. The marked genomic instability during this phase produces a large number of genetic variants. Once a favorable variant has found a way to restabilize its telomeres by either telomerase expression or ALT activation, the tumor enters the next phase of progression.
A role for crisis in melanoma regression is also supported by studies on melanomas arising in Sinclair swine. These animals develop melanomas that spontaneously regress. Studies of these melanomas have shown that regression is paralleled by telomere shortening and chromosome end-to-end fusion (Pathak et al., 2000) . These are changes that are expected to be seen during crisis.
There is no doubt that there is a T-cell response against melanoma antigens (Rosenberg, 2001 ) and that specific T-cells can be found in regressing melanomas (thor Straten et al., 1996) . However, there is increasing evidence that the cadavers of apoptotic cells can induce autoimmunity (Scott et al., 2001) , so that even the fact that these lymphocytes are specific for tumor antigens must not mean that they actually killed the tumor. Antigens released during apoptosis may induce a T-cell response as a secondary reaction. However, if they really contribute to the cell death the transient genomic chaos of crisis would provide a unique opportunity for the evolution of resistant clones. These clones can take advantage of genomic instability to develop immune escape mechanisms such as, for example, loosing HLA class I function (Kageshita et al., 1999) or acquiring defects in apoptosis (Soengas et al., 2001) .
Crisis as an additional or alternate mechanism for regression could explain why regression is tied to a distinct phase of tumor progression.
Field cells: a phase of progression preceding in situ growth When we discovered that AMs had frequent gene amplifications, we tried to determine at which progression stage these amplifications arise. The fact that all AM in our study had at least one, mostly several, amplifications suggested that amplifications arise early during progression. We performed extensive FISH studies on the tumors that we had profiled by CGH to map topographically the amplifications on tissue sections (Bastian et al., 2000a) . We found that the amplifications were present at mostly similar levels in the invasive areas, areas of radial growth, and the in situ portion of the cases. Since the amplifications were already present at the in situ stage, indeed amplifications appeared to arise early in AM. To our surprise, we detected stretches of histologically normal skin adjacent to the melanomas in which basal melanocytes also had amplifications (Figure 1 ). These melanocytes with amplifications were equidistantly spaced as is normal and showed no marked histologic atypicality. The areas with these cells were seen adjacent to the in situ portion, suggesting that they represent a subtle extension of the in situ portion. Theoretically, they could also represent However, this appeared less likely because they were distributed asymmetrically around the invasive portion, as opposed to a concentric distribution, which would be expected if these cells had migrated out from the invasive part. The fact that we found similar cells in AM in situ, which, by definition, does not have an invasive portion, also confirmed that the cells were not metastatic in origin. We termed the genetically aberrant cells extending beyond the histologically detectable portion of a melanoma field cells. Current guidelines for excision of melanoma include safety margins of clinically normal appearing skin of 1-3 cm, depending on the thickness of the melanoma. Typically, the excision margins do not show residual melanoma cells histologically, and the nature of the minimal residual disease that is removed by the safety margins is not known. Field cells could therefore represent the anatomic correlate one type of minimal residual disease. In our series we observed one melanoma that recurred three times at the excision site. Every time a recurrence was excised the margins were free of neoplasm by conventional pathology. However, FISH detected field cells reaching to the peripheral margins in every excision. Although more cases need to be studied, these observations suggest that field cells could be responsible for local recurrences. Current recommendations for safety margins are empirically based on tumor thickness, that is, on the vertical extent of the melanoma. Our data that links minimal residual disease to the in situ portion, suggest that the horizontal extent may be more important to estimate the amount of minimal residual disease.
We have also studied nonacral melanomas for the presence of field cells. However, these studies are more difficult as in acral melanomas because nonacral melanomas do not frequently show gene amplifications. With FISH field cells are best recognized if marked copy number deviations are present. This is because only about one in 10 basal cells is a melanocyte, and no morphological clues that reliably distinguish melanocytes from basal keratinocytes with the FISH counterstain. In order to look for field cells in nonacral melanomas we focused on the 15% of nonacral melanomas that had shown gene amplifications by CGH. Using FISH with probes targeted to the amplified regions we did not find any cells with amplifications in the noninvolved epidermis in these cases. However, different from AM, the nonacral melanomas showed amplifications only within areas of vertical growth but not in the in the in situ portions (unpublished). These findings suggest that different from AM, the amplifications arise later during progression in nonacral melanomas. This is similar to other cancers, in which amplifications are associated with later progression stages and can also have prognostic implications (Brodeur and Hogarty, 1998) . Therefore, the absence of amplifications in the in situ portions of these cases does not rule out the presence of field cells. In order to detect more subtle changes such as loss of one of two copies, one needs to use methods such as a combination of immunohistochemistry and FISH that allow detecting single aberrant cells among many normal cells.
Our current definition of melanocytic neoplasia, whether benign or malignant, requires an increase of melanocyte number relative to the surrounding keratinocytes. Benign lesions with an increased number of basal melanocytes are termed lentigo simplex, or junctional melanocytic nevus, depending on whether single cells or nests of cells predominate. If the melanocytes are increased in number and distributed irregularly or show marked upward scatter the lesion is classified as melanoma in situ. The finding of field cells suggests that there is a progression phase that precedes these stages. At this stage, the melanocytes would be already genetically altered but homeostatic mechanisms were still intact and the melanocyte to keratinocytes ratio was still preserved.
This scenario is somewhat reminiscent of what has been shown for the early progression phases of nonmelanoma skin cancer, in which clonal patches of keratinocytes with p53 mutations are found in sundamaged skin (Ziegler et al., 1994; Brash, 1997) . Analogous to this model one could assume that field cells have a defective response to DNA damage. In the presence of a genotoxic event such as UV irradiation that induces apoptosis or arrest in normal melanocytes suffering DNA damage (Zhai et al., 1996) , these melanocytes would have a selective advantage over their normal neighbors. Subsequent exposures to UV would then be able to 'pump' a field of defective melanocytes, similar to what has been described for keratinocytes. These cells would have lost one important defense mechanism against DNA damage and acquire more genetic alterations. If this leads to the acquisition of a proliferative 'hit' the lesion could be recognized histologically by an increased number of melanocytes within the epidermis. Depending on the type of genetic alterations present and possibly depending on the status of the senescence checkpoints the proliferation could be either benign (lentigo simplex or melanocytic nevus) or malignant (melanoma). The presence of the clonal field therefore does not necessarily imply melanoma.
It seems likely that many of these fields are acquired during life, and that the number and size of fields increases with accumulating sun exposure. For the p53-mutated keratinocytes patches it has been shown that they can reach a density of up to 40/cm 2 in chronically sun-exposed skin (Brash and Ponten, 1998) . One might speculate that if fields are acquired early in life, at a time when the body surface is still small, fields may expand significantly during growth until adulthood. This would result in a significant increase in target cells for subsequent damage, and might explain why sun exposure in childhood is associated with a greater melanoma risk. All this is purely speculative, and an extrapolation from the field cells that we have observed in acral melanomas. However, as this could have important implications in our surgical management of melanoma and our understanding of early melanoma development, further studies of this phenomenon are warranted.
